Laser correction procedure for pain syndrome

FIELD: medicine.

SUBSTANCE: correction of pain syndrome accompanying severe psoriasis is ensured with skin irradiation within affected region or above inflammatory tissue using low intensity IR rays of CO2 laser. Laser wavelength is 10.6 mcm. Radiation power density in pulse-periodic regime is 0.015-1 Wt/cm2, radiation pulse duration is 0.5-10 mc, pulse window is 10-100 mc, and highly directional IR radiation divergence is 10-2 radians. While radiation, laser beam is moved on skin within affected region during 5-10 minutes, herewith zone exposure duration determined by laser beam diameter is 1-2 sec. Skin is preliminary coated with adenosine triphosphate with daily exposure within course of 10-15 days.

EFFECT: evident reparative analgesic effect, reduced time of hospital stay, prevention of complications.

1 ex


The invention relates to medicine, in particular to a method of laser correction of pain syndrome in severe forms of psoriasis.

Characteristic radiation of CO2laser having a wavelength of 10.6 μm, is its strong absorption by biological tissues, which is caused by the absorption of the contained water molecules. At a wavelength of 10.6 µm water absorption ratio μand=856,7 cm-1. The characteristic penetration depth of the radiation CO2laser in water L=1/μandon which the radiation intensity decreases 2.73 times, is ˜12 μm. With strong absorption and low scattering of radiation CO2laser in biological tissues is associated its use primarily in surgery as a "light scalpel".

Informed use of laser radiation to reduce (edema) pain became possible after it was found that peripheral nerves and neurons sensitive to light. In 1971 there was a message about the change in the activity of cells isolated abdominal ganglion Aplysia when exposed to radiation of an argon laser (Folk R.J. Laser stimulation of nerve cell Aplysia // Science. 1971. V.I 71. P.907-908).

When comparing the responses of a neuron to the action of radiation of the near and middle infrared bands, it was found that the threshold density is here the power of radiation, calling the response of the neuron is reduced by seven orders of magnitude, from 0.45 to 2×10-8W/cm2when the transition from the spectral range of 0.8-3 μm to a wavelength of CO2laser (10.6 μm). This fact is testified to the existence of the mechanism of high spectral selectivity of the membrane of a neuron (Pavlenko and others, Thermoreceptors function of the receptor of the crayfish stretch // Physiological journal of the USSR. I.M. Sechenov. LXI. 1975. No. 6. S-932).

The influence of low-intensity infrared radiation on neurons warm-blooded animals was studied by using the method of local fixation potential (patch - clamp method), studied the influence of infrared radiation spectral range 1-56 μm on slow sodium channels in cultured dissociated neurons in spinal ganglia of the rat (Plakhova V.B. have been and other Possible mechanisms of action of infrared radiation on the membrane of the sensory neuron // Sensory systems. 2003. V.17. N 1. P.24-31).

The methodology used allowed us to obtain quantitative data about the response of the neuron's membrane by the action of radiation by measuring a threshold of potentialcustomers activation of the portal system of slow sodium channels. The results of these studies have attested to the fact that the infrared radiation reduces the value of the threshold potentiometricdetermination portal device slow sodium channels (Na v1.8). The effect of radiation was removed by ouabain, a specific blocker of Na,K-ATPase, which confirmed its participation in the "reception" of IR radiation. Na,K-ATPase is a membrane structure of a neuron that performs the function of the ion pump and transducer signal, regulating the activation of the portal system of slow sodium channels responsible for the coding of the pain signal (Krylov BV and other Morphine reduces sensitivity to potential slow sodium channels // Russian Fiziol. the log them. I.M. Sechenov. 1999. T, No. 2. S-236).

Exposure to nerve cells by radiation of CO2laser leads to a range of consecutive physical and physiological processes. Primary among them is the absorption of radiation by molecules of ATP, due to their vibrational absorption bands in the middle infrared (IR) region of the spectrum. Energy is released in the enzymatic hydrolysis of ATP


The enzyme reaction is Na,K-ATPase is a transmembrane protein that performs a "pumping" function and that is especially important in our consideration, transductor function. Its inclusion is due to the hydrolysis reaction of "active" molecules of ATP with after exposure to IR radiation some excess energy - activation energy (Ea). The conditions under which which the activation energy is determined energies only translational motion of the molecules, the rate constant of hydrolysis is determined by the expression (NR. Kondrat'ev, 1974)


in which A - pre-exponential factor, T is the temperature, R is the universal gas constant.

Absorbing the radiation of the ATP molecule acquires additional energy and goes into an excited vibrational state. The hydrolysis rate of the excited molecules increases. This is because if the molecules internal (vibrational and rotational) energy exceeding the energy of the translational motion, the dependence of the rate constant on temperature is more strong

k=ATnexp(-Ea/RT), n>1.

Transductor function of Na,K-ATPase in this case is to strengthen incident on the membrane of a nerve cell signal, emitted low-intensity radiation in the IR range. In addition, the Na,K-ATPase as transducer transmits a signal next to the membrane ion channels that regulate their excitability. The action of radiation, increasing the rate of ATP hydrolysis and, consequently, increasing energy input Na,K-ATPase in a unit of time, accompanied by a decrease in excitability it is slow sodium channels responsible for the coding of the pain signal (Krylov BV and other Morphine reduces sensitivity to potential slow Natrii the x channels // Russian Fiziol. the log them. I.M. Sechenov. 1999. T, No. 2. S-236).

The closest prototype of the adopted method of laser correction of pain syndrome in patent RU No. 2296596, including local irradiation of the skin in the affected area of low-intensity Visakhapatnam infrared CO2laser at a wavelength of 10.6 microns in the pulse-periodic mode. However, the prototype does not allow you to adjust pain syndrome, in particular, psoriatic arthritis and several other syndromes with impaired cellular process of oxidative phosphorylation.

The inventive method of treatment of patients with severe forms of psoriasis, including irradiation of the skin in the affected area of low-intensity Visakhapatnam infrared CO2laser at a wavelength of 10.6 microns in the pulse-periodic mode, implement the irradiation from 5 to 10 minutes daily, moving the beam of laser radiation on the skin in the affected area by 1-2 stops, with the following parameters: beam divergence of 10-2glad pulse duration of the radiation of 0.5 to 10 MS and the duration of pauses between 10-100 MS, the power density of 0.015-1 W/cm2and before irradiation is applied to the skin of ATP, performing a course of 10-15 sessions. The ATP content in the grease from 0.09% to 30% depending on severity.

This set of essential features of the claimed act which provides both the technical result - possible non-drug, non-invasive correction of the pain syndrome in severe forms of psoriasis, comparable in strength to act "big" analgesics. The proposed method does not violate the physiological status and the integrity of the body and has no negative side effects (addiction, the need for a gradual increase in dose, the reactions of the autonomic nervous system and higher emotional centers), reflected in the constant use of "big" analgesics. Pain is eliminated much faster than when using classical tools of pharmacology.

This technical result is determined not previously known laser irradiation with the original parameters, exogenous introduction of ATP through the skin in the affected area (by electrophoresis or by percutaneous introduction ATP-containing ointments). The authors described the mechanism of interaction of radiation WITH2laser with the membrane of nerve cells and an explanation of the achieved effect.


Treatment with IR laser was performed in patients with severe forms of psoriasis in age from 21 to 65 years. Duration of illness ranged on average from 3 to 20 years. Provoking factors of the disease were: nervous stress, colds, exacerbation of hronicheskoj the gastritis, diseases of the hepatobiliary system, the intake of alcohol. Seasonal psoriasis was diagnosed in 72% of patients, the off-season at 28%. Family nature of psoriasis is set at 19.2% of all patients. The vast majority of patients were male (75%), and persons of working age was 83%. Skin lesion in all patients had widespread in the form of large plaques or diffuse lesions, often with a partial erythroderma. In 85% of patients the disease was in an advanced stage, and 15% in stationary. 40% of the observed patients were observed phenomena asthenia, complaints of itching of the skin in the area of lesions. All patients with psoriasis the process on the skin was characterized by resistance to traditional therapies (vitamins, sedatives and hyposensitizing means CRF). The drugs, steroid and immunotropic drugs previously taken with a temporary effect 67% of patients, photochemotherapy - 15%. In 23% of patients had no remission for 3 years. The duration of relapse over 12 months detected in 47% of patients.

Irradiation with a laser was performed according to the type of the local impact of lesions, pain points. All these sites were initially subjected to percutaneous introduction of ATP using iontophoresis or through the use of ATP-containing ointments. The ATP content is ointment - from 0.09% to 30% depending on the severity of the pathological area. Initial exposure time ranged from 5 min to 10 min, depending on the initial condition of the patient, the activity of the process (with greater severity of the inflammatory process initial exposure time was less). The total exposure per procedure depended on the number and size of lesions. The total time of the session of physical therapy is standard for these types of procedures. The course of treatment was 10-15 days. Physiotherapeutic procedure was performed every day.

When performing method is the improvement of the General condition 2-3 days after the start of treatment. First of all, no feeling of weakness, malaise, decreased the intensity of itching, especially at the exudative forms of psoriasis, there was a General emotional lift. 4-5 procedure continued emergence of fresh papules, was a decrease in infiltration, scaling, intensity of colour of psoriatic lesions disappeared signs of inflammation on the joints, decreased arthralgia. To 10 days of therapy was noted marked regression of psoriatic items disappeared arthralgia. In patients with psoriatic arthritis (inflammatory and degenerative radiographic pattern of joint damage) by the 15th session noted the recovery of the amount of motion is in the affected joint.

Reduced length of stay of patients in hospital on average 7-10 days. Clinical improvement was noted in 58%, clinical improvement in 43% of patients. Complications and side effects of therapy were observed. Tolerability was good. Therapy has virtually no age restrictions. It is advisable to apply it to patients other treatments are contraindicated or had no effect.

The study was conducted action of pulsed low-intensity CO2laser in patients with psoriatic arthritis and trophic ulcers of the lower extremities. The study included 15 patients with psoriatic arthritis distal and proximal interphalangeal joints of the hands and feet, as well as the elbow and knee joints. The vast majority were women. Disease duration ranged from 6 months to 10 years. Source all patients underwent laboratory examination to exclude diseases with high inflammatory and immune activity of joint damage, clinical examination with assessment of pain by visual analogue scale (VAS) in millimeters at rest and during exercise, x-rays of the affected joints was carried out only during the initial visit. Patients with trophic ulcers of the lower legs were three women over the age of 60 years, with disease duration from 10 to 3 years. Everything aziende suffered from varicose disease. Laser irradiation was carried out according to the type of the local impact of lesions, pain points. Irradiation duration of one field ranged from 1 to 4 minutes, total time of exposure per procedure did not exceed 15 minutes. Laser therapy was performed daily. The average number of procedures in the course of treatment is 12-15. Results: before treatment, the clinical symptoms of psoriatic arthritis is characterized by joint pain, morning stiffness, increase the circumference of the joints, limited movement in the joint. Pain at rest on the scale of YOUR totaled 38.2 mm, the motion - 59,0 mm, palpation - 41,3 mm After the first 4-5 procedures all patients reported a significant decrease in pain, which was quite apparent in the first 2 -3 hours after a session, but gradually increased to the beginning of the next session, although, in General, pain intensity was below its initial level, there has been a decrease in feelings of tightness, swelling of the joints. On the scale of YOUR pain alone amounted to 28.2 mm, the motion - 44 mm, palpation 36,3 mm

Clinical improvement after a course of laser therapy was achieved in all patients. Notable reparative and analgesic effect was observed in patients with trophic ulcers, which allowed for a course to reduce 3-4 times square ulcers, to achieve four is investing a good granulation, to reduce the swelling of the affected limb.

A method for the treatment of patients with severe forms of psoriasis, including irradiation of the skin in the affected area of low-intensity Visakhapatnam infrared CO2laser at a wavelength of 10.6 microns in the pulse-periodic mode, characterized in that

irradiated daily for 5 to 10 minutes, moving the beam of radiation on the skin in the affected area with stops at 1-2 s, and:

the divergence vysokonapornogo radiation 10-2glad,

the pulse duration of the radiation of 0.5 to 10 MS, and the duration between pulses of 10-100 MS,

the power density of 0.015-1 W/cm2,

before irradiation is applied to the skin of ATP, and

the course of treatment is 10-15 days.


Same patents:

FIELD: medicine; surgery.

SUBSTANCE: adhesion therapy following thoracic and abdominal organs surgery is ensured with multiple daily applications of Tizol gel and salicylic acid mixed as: salicylic acid 0.2 g and Tizol gel to 10 g, thus coating incision cicatrix and skin, adjacent anterior abdominal wall or thorax part over lesion focus. Thereafter within three months, multiple daily applications of medicinal composition containing Tizol gel and Lidase mixed as: Lidase 128 st.units per Tizol gel 10 g are used for the indicated regions. Herewith three physiotherapeutic procedures are performed every two weeks as follows: either phonophoresis, or electrophonophoresis, or electrodreging with the specified composition containing Tizol gel and Lidase.

EFFECT: creation of medical product depot directly within pathological process, long-acting and continuously pathogenetic affecting connective tissue and preventing adhesions.

3 cl, 9 ex

FIELD: chemistry.

SUBSTANCE: description is given of diazepane derivatives with formula I where R1 stands for C1-C4alkyl, R2 stands for unsubstituted C1-C4alkyl or C1-C4alkyl, substituted with quinolinyl, benzo[1,3]dioxolyl, phenyl, phenyl, substituted with 1-3 substitutes, chosen from a group, comprising halogen, halogen(C1-C4)alkyl, C1-C4alkoxy, cyano, amino, dimethylamino, carboxy(C1-C2)alkylcarbonylamino, amino(C1-C2)alkylcarbonylamino, C2-C4alkylenecarbonylamino, heterocyclylcarbonyl(C1-C2)alkylcarbonylamino, where heterocyclyl contains 6 atoms in the ring and 2 heteroatoms, chosen from N or N and O, R3 stands for phenyl, substituted with one or two substitutes, chosen from a group, comprising halogen, halogen(C1-C6)alkyl, halogen(C1-C6)alkoxy, cyano, phenyl or aromatic heterocyclyl, containing 6 atoms in a ring and two nitrogen heteroatoms.

EFFECT: obtaining compounds with inhibiting effect on LFA-1/ICAM-1.

6 cl, 1 tbl

FIELD: chemistry.

SUBSTANCE: present invention pertains to derivatives of 1-(4-benzylpiperazin-1-yl)-3-phenylpropenone, which are antagonists of the chemokine (CCR-1) receptor, with general formula I or its pharmaceutical salts or ester, where substitutes are defined in the description text. The invented compounds can be used for making pharmaceutical compositions, as well as in pharmaceutics for making medicinal agents, with inhibiting effect on chemokine (CCR-1) receptors.

EFFECT: obtaining compounds, used as medicinal agents, with inhibiting effect on chemokine receptors.

10 cl, 113 ex

FIELD: chemistry.

SUBSTANCE: invention concerns new compounds of the formula (I), their isomers and pharmaceutically acceptable salts. In the general formula (I) A is (II) ; X1 is methylene; X2 is CN, CHO, C(O)R6; X6 is a link; R1 is R13C(O)-; R2 is hydrogen; R3 is selected out of group including H, phenyl-(C0-6)alkyl, (C1-6)alkyl, optionally substituted by -X6OR9 group; R4 is H or (C1-6)alkyl; or R3 and R4 form (C3-8)cycloalkylene together with carbon atom to which R3, R4 are linked; R5 is (C1-9)alkyl, benzyl. Invention also concerns compounds of formulae (la), (lb), (Ic), and pharmaceutical composition based on the claimed compounds.

EFFECT: new compounds inhibiting cathepsin.

22 cl, 2 dwg, 89 ex

FIELD: chemistry.

SUBSTANCE: description is given of a piperidine derivative with general formula (I) , where L represents CH or N; M represents CH or N; under the condition that, L and M both do not represent CH; R1 represents phenyl (possibly substituted with a halogen or C1-4alkyl), S(O)2(C1-4alkyl), S(O)2(C1-4fluroalkyl), S(O)2phenyl (possibly substituted with CF3 or OCF3), benzyl, benzoyl (possibly substituted with a halogen) or C(O)NHphenyl (possibly substituted with a halogen); R2 represents phenyl, possibly substituted with a halogen; R3 represents hydrogen or C1-4alkyl; R4 represents methyl or ethyl; R5 represents phenyl-NH, phenyl (C1-2alkyl), phenyl(C1-C2)alkyl-NH or pyridyl(C1-2alkyl). The phenyl can be substituted with a halogen, cyano, C1-4alkyl, C1-4alkoxy, S(O)k(C1-4alkyl) or S(O)2NR8R9; k is equal to 2; R8 and R9 represent hydrogen or its pharmaceutical salts. The compound is a modulator of the activity of the CCR5 receptor. Description is given of the method of obtaining the compound, where L represents N, and the pharmaceutical composition based on a compound with formula (I).

EFFECT: design of a method of obtaining a compound, where L represents N, and a pharmaceutical composition based a compound with formula (I).

7 cl, 7 tbl, 16 ex

FIELD: medicine; pharmacology.

SUBSTANCE: substance of invention includes human polypeptide or its functional fragment containing sequence SEQ ID NO:2 or polynucleotide-encoded, containing sequence corresponding to SEQ ID NO:1. Furthermore, the invention includes methods of abatement and compound screening which can be used for modulation or pain prevention.

EFFECT: extended application.

30 cl, 1 tbl, 14 dwg

FIELD: medicine; pharmacology.

SUBSTANCE: agent contains Meloxicam as active substance, sodium chloride, glycine, glycofurol (tetraglycol), poloxamer (luthrol), methyl glucamine, sodium hydroxide and water for injection as additives. Glycofurol and poloxamer ratio is 2:1. New formulation of Meloxicam represented with intramuscular injected solution is produced.

EFFECT: higher efficiency of treatment of arthropathy accompanied with pain syndrome.

FIELD: medicine; pharmacology.

SUBSTANCE: compounds can be applied as medical products for treating the diseases associated with PMN chemotaxis caused with IL-8, including psoriasis, rheumatoid arthritis, and ulcerative colitis, and for treating the damages caused by ischemia and reperfusion. In formula , Ar represents phenyl optionally substituted with one to three substitutes which can be the same or differ from each other, chosen of: halogen, C1-C4-alkyl, C1-C4-alkoxy, hydroxy, C1-C4-acyloxy, phenoxy, cyano, nitro, amino, C1-C4-acylamino, halogen-C1-C3-alkyl, halogen-C1-C3-alkoxy, benzoyl; or Ar represents 4-thienoylphenyl, 4-(1-oxo-2-isoindolynil)phenyl, 3-chlorine-4-(2,5-dihydro-1H-pyrrole-1-yl)phenyl, 6-methoxy-β-naphthyl, 1-hydroxyphenyl-1-methyl; or Ar represents group of formula III where A represents benzyl, phenoxy, benzoyl, benzoyloxym, 1- hydroxyphenyl-1-methyl; B represents hydroxy, C1-C4-acyloxy or group of formula -O-C(=S)-N(CH3)2, or -S-C(=O)-N(CH3)2; Ra and Rb are independently chosen from the group including hydrogen, linear or branched C1-C6-alkyl, phenyl, α- or β-naphthyl, 2,3,4-pyridyl, C1-C4-alkylphenyl, C1-C4-alkyl (α- or β-naphthyl), C1-C4-alkyl (2,3,4-pyridyl), cyano (-CN), carboxamide, carboxyl or carboxy esters of formula CO2R" wherein R" represents residue linear or branched aliphatic C1-C6-alcohol, phosphonate PO(OR")2, where R" has specified values, or formula of group X-(CH2)n-Z, where X represents C, SO or SO2 group; Z represents hydrogen, tert-butyl, isopropyl, CO2R", CN, phenyl, α- or β-naphthyl, 2,3,4-pyridyl, C3-C6-cycloalkyl, NH-BOC, NH2; n is equal to zero or integer within 1 to 3; or Ra and Rb together with carbon atom whereto attached form cyclic residue 2,2-disubstituted 4,6-dioxo-1,3-dioxanyl of formula, II where R' represents methyl or ethyl, or two groups R' form cyclohexane or cyclopentane ring.

EFFECT: higher efficiency of treatment.

7 cl, 15 ex

FIELD: chemistry, pharmaceutics.

SUBSTANCE: invention relates to novel compounds N(1,3-tiazol-2-yl)amides of 2-diphenylmethylenehydrazono-5,5-dimethyl-2,4-diooxohexane acid of formula (Ia, b): demonstration anti-inflammatory and analgetic activity. Invention also relates to method of their obtaining.

EFFECT: obtaining novel compounds.

2 cl, 1 tbl, 2 ex

FIELD: chemistry, pharmaceutics.

SUBSTANCE: described is application of sulfonic acids and their derivatives of formula (I) and pharmaceutically acceptable salts of said compounds (see radical values in invention formula) for obtaining medication for inhibition of human PMN chemotaxis, induced by IL-8 and sulfonic acids and their derivatives of formula (I). Described are three methods of obtaining of the said compounds and pharmaceutical composition based on them.

EFFECT: compounds of formula (I) possess inhibiting activity of human PMN chemotaxis.

11 cl, 2 tbl, 6 ex

FIELD: medicine; physiotherapy.

SUBSTANCE: ultrasonic inhalations of 10 ml solution of 1% placenta hydrolyzate are applied at temperature of solution 35°C within 10 minutes. Procedure is applied in the morning on an empty stomach, or 40-60 minutes after eating. It is followed with scanning laser therapy with infra-red laser radiation from laser scanning physiotherapeutic stimulator LSPS-03.2IR. Output power at light guide end is 2 mWt, power flux density is 50 mWt/cm2. While exposure the patient is positioned lying on stomach, thus effecting paravertebral fields to the right and to the left at level D3-D9, within 3 minutes per each field. Then while the patient is positioned lying on back, liver region is exposure within 8 minutes. Course is 10 daily procedures.

EFFECT: normalised eliminative properties of epithelial barrier of a respiratory tract and local immunity of airway mucous membrane.

3 tbl, 2 ex

FIELD: medicine; dentistry.

SUBSTANCE: treatment of inferior dental nerve neuritis caused by filling material delivery into mandibular canal is ensured with introduction of antibacterial agent before operation. Thereafter filling material is surgically removed from mandibular canal. Operation procedure is followed with introduction of antibacterial and immune correcting agents, antisensitisers, Reaferone, vitamins B1 and B12, adenosine triphosphate. Besides mandibular region is exposure to laser magnetotherapy with using dental apparatus Optodan, accompanied with intraoral HBO-therapy, hydromassage, hydrocortisone phonophoresis, 2% nicotinic acid solution amplipulse phoresis, Tambukan mud therapy, pine needle and pearl baths, acupuncture with using local and regional points.

EFFECT: higher treatment efficiency, restored blood circulation, accelerated rehabilitation, complete relief of evident pain syndrome and post-amputation pains, simplicity, efficiency.

3 ex

FIELD: medicine; pulmonology.

SUBSTANCE: intravenous laser irradiation of blood (ILIB) is carried out differentially depending on detected hemodynamic type of microcirculation and level of protein C system activity. In case of hyperemic, spastic and normocirculatory hemodynamic type of microcirculation and activity level of protein C system of 0.704±0.02 and higher, 7 sessions of ILIB are performed. In case of stasis and stagnant hemodynamic type of microcirculation and activity level of protein C system less than 0.704±0.02, 12 sessions of intravenous laser irradiation of blood. Length of wave is 0.63 mcm, intensity of irradiation at light guide end makes 1.5-2.0 mW, one procedure per day, duration makes 20 minutes.

EFFECT: lower demand in antibacterial therapy and in medicines of pathogenetic action, lower medicamental load on patient and reduction of disease clinical symptoms preservation duration.

5 tbl, 2 ex

FIELD: medicine; gynaecology.

SUBSTANCE: solution of photosensitiser "Photoditazine" is introduced intravenously in dose of 0.5-1.0 mg/kg. As soon as 1.5-2 hours have elapsed after infusion, intrauterine light guide is inserted into uterine cavity, and uterine cavity is radiated with laser in fractions at wave length of 662 nm and density of supplied energy of 200 - 350 J/cm2 for 30-45 minutes. After uterine cavity has been radiated, cervical channel is radiated in fractions by laser with application of cylindrical light guide at wave length of 662 nm and density of supplied energy of 200-250 J/cm2 for 15-30 minutes.

EFFECT: highly selective removal of functional and basal layer of uterus mucous layer.

3 ex

FIELD: medicine; oncology.

SUBSTANCE: method includes introduction of solution of chemical compound of amino acid L-phenylalanine with gold or silver nanoparticles intravenously prior to radiation. At that minimum concentration of nanoparticles is 108 cm-3, and maximum concentration is 1012 cm-3. Plasma resonance of nanoparticles has spectral maximum in the area of biotissues transparency at the wave length of 750-1200 nm. These nanoparticles are gold or silver nanoshells with core of silicon dioxide or nanorods. Radiation of melanoma is performed at least after 1 hour and not more than after 4 hours after solution introduction, laser beam with length of radiation wave that coincides with spectral maximum of nanoparticles plasma resonance absorption. At that radiation is done by sequence of laser impulses with duration of laser impulse in the range of 10 microseconds - 100 ns at minimum porosity of three and higher, at energy density of at least 20 J/cm2, but not more than 200 J/cm2.

EFFECT: local performance of melanoma destruction with minimum destruction of surrounding healthy cells.

10 dwg

FIELD: medicine; therapy and cardiology.

SUBSTANCE: biophysical indices are determined in points of heart and pericardium meridians acupuncture. Corporal points of heart and pericardium meridians acupuncture are exposed to laser radiation with wave length of 0.63 mcm with outlet power density of 0.1-10 mW/cm2 and beam diameter of 1.5-0.1 mm. Radiation is dosed according to dynamics of electropotential value in every point of acupuncture. Laser therapy is carried out in combination with intake of activated acid and alkaline water according to regimen that provides rise in consumption of acid water from 1/3 of glass to 1/2 of glass - in the end of treatment, and alkaline water from 1 to 7-8 glasses accordingly. The whole course is realised against the background of diet with reduction of food calorie and fat content and graduated physical exercise.

EFFECT: normalisation of vessel walls elasticity, better tolerance of physical activity.

1 ex

FIELD: medicine.

SUBSTANCE: treatment of glial brain tumours is ensured by partial tumour extraction. During operation photosensitiser is delivered in the cavity formed by partial tumour extraction. Photodynamic laser therapy implies using diode laser of cylindrical diffuser with spherical radiation pattern. Wavelength is 660 nm, power is 100-200 mW.

EFFECT: higher concentration of photosensitiser in cavity of partially extracted tumour, reduced amount of introduced photosensitiser, more uniform radiation of tumour tissue, lower probability of postoperative complications and length of hospital stay.

3 ex

FIELD: medicine; ophthalmology.

SUBSTANCE: invention can be used for surgical treatment of central vein thrombosis of retina (RCV). Induction of chorioretinal anastomosis (CRA) is performed by laser radiation of RCV of the third order with wave length 532 nm, four coagulates in number, radiation power density 500 mW/cm2, pulse duration 1 second, spot diameter 50 mcm. Vitrectomy is preliminary carried out with removed posterior hyaloid membrane of vitreous body. It is followed with perioperative endolaser CRA induction and, additionally paravasal endolaser retina coagulation at wave length 532 nm, 500-600 coagulates in number, radiation power density 120-200 mW/cm2, pulse duration 0.1-0.2 seconds, spot diameter 50-200 mcm.

EFFECT: higher efficiency of surgical treatment of RCV thrombosis based on combined vitrectomy, removal of posterior hyaloid membrane of vitreous body (PHMVB), perioperative endolaser CRA induction and paravasal panretinal endolaser retina coagulation.

3 ex

FIELD: medicine.

SUBSTANCE: invention refers to development of noninvasive selective optical haemodialysis of human blood elements based on offered photothermolysis of sickle cells conjugate with negative golden nanoparticles exposed to lasing at wave length coinciding with plasmon nanoparticles resonance. Blood is introduced with golden nanoparticles and exposed to lasing at wave length coinciding with spectral maximum absorption of plasmon nanoparticles resonance and causing cell photothermolysis. Before blood is introduced with nanoparticles, their surface is negative charged comparable to membrane potential of normal erythrocytes to provide physical adhesion to plasma membrane of pathologic cells, specifically of sickle-cell erythrocytes, of nanoparticles concentration in pH neutral physiological solution with erythrocyte concentration order. Venous blood running through catheter and containing human sickle-cell erythrocytes is exposed to radiation. Herewith nanoparticles is characterised with plasmon resonance within human tissue transmission region 700-1100 nm. Laser pulse duration is to be within 10 mcs-100 ns at energy density in laser pulse not exceeding 100 mJ/cm2 and laser pulse porosity at least 3. Nanoparticles represent silica nuclei in diameter 50-140 nm of silicon dioxide coated with a gold or silver of thickness within 2-20 nm, or gold or silver nanorods characterised by length to diameter ratio within 2.5 to 5 and diameter 10-40 nm.

EFFECT: selective disintegration of pathologic human blood erythrocytes not capable for oxygen migration based on selective laser photothemolysis of sickle-cell erythrocytes connected to nanoparticles during pulse lasing of blood stream in vivo.

3 cl, 6 dwg

FIELD: medicine; endocrinology.

SUBSTANCE: cold scattered laser radiation is used at wave length 0.89 mcm and power 2 Wt. Contact cutaneous technique is used for irradiation in projection of lobes of thyroid gland at exposition 3-4 minutes per each lobe. According to disease severity level, for the first 5-10th sessions radiation 3000 Hz is used, while thereafter till the last procedure, radiation frequency is reduced to 300 Hz. For the patient with mild severity level of disease, laser therapy is applied as independent method of treatment. Though for the patient with moderate severity level of disease, laser therapy is combined with nonsteroid anti-inflammatory preparations (NAIP). Thus to patients with moderate severity level of disease, Ortofen dosed 3 ml 1-2 times a day is intramuscularly injected as NAIP. For the patient with severe disease, laser therapy and NAIP is added with introduction into thyroid gland of Kenalog dosed 20 mg per each lobe dissolved 1:1 with 0.5% novocaine solution 1 to 3 times every 5-7 days.

EFFECT: reduced treatment time.

3 ex

FIELD: chemistry.

SUBSTANCE: present invention pertains to ester lipids of halogenated adenine nucleotides with formula I, which can be used in treating cancerous diseases. (I), where R1 - C1-C20-alkyl, can be substituted with C1-C6-alkoxyl radical, C1-C6-alkylmercaptan radical, C1-C6-alkylsulfenyl or C1-C6-alkylsulfonyl groups, R2 - C1-C20-alkyl, which can be substituted with C1-C6-alkoxyl radical, C1-C6-alkylmercaptan radical or C1-C6-alkylsulfonyl group, R3 - amino group, X - sulphur atom, sulfenyl or sulfonyl group, Y - oxygen atom.

EFFECT: obtaining new biologically active compounds.

3 cl, 9 ex, 1 tbl